Cargando…

Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment

There are limited data on the safety and efficacy of immunotherapy for patients with advanced pancreatic cancer (APC). A meta-analysis of single-arm trials is proposed to assess the efficacy and safety of immunotherapy for APC. Eighteen relevant studies involving 527 patients were identified. The po...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Bin, Dong, Yuhao, Liu, Jing, Lian, Zhouyang, Liang, Long, Chen, Wenbo, Luo, Xiaoning, Pei, Shufang, Mo, Xiaokai, Zhang, Lu, Huang, Wenhui, Ouyang, Fusheng, Guo, Baoliang, Liang, Changhong, Zhang, Shuixing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351583/
https://www.ncbi.nlm.nih.gov/pubmed/27992378
http://dx.doi.org/10.18632/oncotarget.13968
_version_ 1782514784793526272
author Zhang, Bin
Dong, Yuhao
Liu, Jing
Lian, Zhouyang
Liang, Long
Chen, Wenbo
Luo, Xiaoning
Pei, Shufang
Mo, Xiaokai
Zhang, Lu
Huang, Wenhui
Ouyang, Fusheng
Guo, Baoliang
Liang, Changhong
Zhang, Shuixing
author_facet Zhang, Bin
Dong, Yuhao
Liu, Jing
Lian, Zhouyang
Liang, Long
Chen, Wenbo
Luo, Xiaoning
Pei, Shufang
Mo, Xiaokai
Zhang, Lu
Huang, Wenhui
Ouyang, Fusheng
Guo, Baoliang
Liang, Changhong
Zhang, Shuixing
author_sort Zhang, Bin
collection PubMed
description There are limited data on the safety and efficacy of immunotherapy for patients with advanced pancreatic cancer (APC). A meta-analysis of single-arm trials is proposed to assess the efficacy and safety of immunotherapy for APC. Eighteen relevant studies involving 527 patients were identified. The pooled disease control rate (DCR), overall survival (OS), progression free survival (PFS), and 1-year survival rate were estimated as 59.32%, 7.90 months, 4.25 months, and 30.12%, respectively. Subgroup analysis showed that the pooled OS, PFS, and 1-year survival rate were significantly higher for autologous activated lymphocyte therapy compared with peptide-based vaccine therapy (OS: 8.28 months vs. 7.40 months; PFS: 6.04 months vs. 3.86 months; 1-year survival rate: 37.17% vs. 19.74%). Another subgroup analysis demonstrated that the pooled endpoints were estimated as obviously higher for immunotherapy plus chemotherapy compared with immunotherapy alone (DCR: 62.51% vs. 47.63%; OS: 8.67 months vs. 4.91 months; PFS: 4.91 months vs. 3.34 months; 1-year survival rate: 32.32% vs. 21.43%). Of the included trials, seven trials reported no treatment related adverse events , five trials reported (16.6 3.9) % grade 3 adverse events and no grade 4 adverse events. In conclusion, immunotherapy is safe and effective in the treatment of APC.
format Online
Article
Text
id pubmed-5351583
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53515832017-04-13 Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment Zhang, Bin Dong, Yuhao Liu, Jing Lian, Zhouyang Liang, Long Chen, Wenbo Luo, Xiaoning Pei, Shufang Mo, Xiaokai Zhang, Lu Huang, Wenhui Ouyang, Fusheng Guo, Baoliang Liang, Changhong Zhang, Shuixing Oncotarget Research Paper There are limited data on the safety and efficacy of immunotherapy for patients with advanced pancreatic cancer (APC). A meta-analysis of single-arm trials is proposed to assess the efficacy and safety of immunotherapy for APC. Eighteen relevant studies involving 527 patients were identified. The pooled disease control rate (DCR), overall survival (OS), progression free survival (PFS), and 1-year survival rate were estimated as 59.32%, 7.90 months, 4.25 months, and 30.12%, respectively. Subgroup analysis showed that the pooled OS, PFS, and 1-year survival rate were significantly higher for autologous activated lymphocyte therapy compared with peptide-based vaccine therapy (OS: 8.28 months vs. 7.40 months; PFS: 6.04 months vs. 3.86 months; 1-year survival rate: 37.17% vs. 19.74%). Another subgroup analysis demonstrated that the pooled endpoints were estimated as obviously higher for immunotherapy plus chemotherapy compared with immunotherapy alone (DCR: 62.51% vs. 47.63%; OS: 8.67 months vs. 4.91 months; PFS: 4.91 months vs. 3.34 months; 1-year survival rate: 32.32% vs. 21.43%). Of the included trials, seven trials reported no treatment related adverse events , five trials reported (16.6 3.9) % grade 3 adverse events and no grade 4 adverse events. In conclusion, immunotherapy is safe and effective in the treatment of APC. Impact Journals LLC 2016-12-15 /pmc/articles/PMC5351583/ /pubmed/27992378 http://dx.doi.org/10.18632/oncotarget.13968 Text en Copyright: © 2017 Zhang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zhang, Bin
Dong, Yuhao
Liu, Jing
Lian, Zhouyang
Liang, Long
Chen, Wenbo
Luo, Xiaoning
Pei, Shufang
Mo, Xiaokai
Zhang, Lu
Huang, Wenhui
Ouyang, Fusheng
Guo, Baoliang
Liang, Changhong
Zhang, Shuixing
Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment
title Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment
title_full Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment
title_fullStr Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment
title_full_unstemmed Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment
title_short Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment
title_sort immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351583/
https://www.ncbi.nlm.nih.gov/pubmed/27992378
http://dx.doi.org/10.18632/oncotarget.13968
work_keys_str_mv AT zhangbin immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT dongyuhao immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT liujing immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT lianzhouyang immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT lianglong immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT chenwenbo immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT luoxiaoning immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT peishufang immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT moxiaokai immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT zhanglu immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT huangwenhui immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT ouyangfusheng immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT guobaoliang immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT liangchanghong immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment
AT zhangshuixing immunotherapyforpatientswithadvancedpancreaticcarcinomaapromisingtreatment